Clinical Management of Argatroban in Patients With Heparin Induced Thrombocytopenia Type II

Heparin-induced Thrombocytopenia Type II Clinical Trial

Official title: An Open-label, Multi-centre, Clinical Study to Collect Information on the Clinical Use of Argatroban in Patients With Heparin Induced Thrombocytopenia (HIT) Type II Who Require Parenteral Antithrombotic Therapy

Status Completed

Clinical Trial Summary

The purpose of this study is to collect data on the clinical management of Argatroban in patients with suspected or confirmed heparin-induced thrombocytopenia Type II, with or without ongoing thrombosis who require parenteral antithrombotic therapy

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Heparin-induced Thrombocytopenia Type II
• Thrombocytopenia
• Thrombocytosis

• NCT number: NCT00861692
• Study type: Interventional
• Source: Mitsubishi Tanabe Pharma Corporation
• Status: Completed
• Phase: Phase 2
• Start date: April 2009
• Completion date: February 2011